Alameda, CA, October 12, 2006 -- Advanced Cell Technology, Inc.'s (OTCBB:ACTC) Robert Lanza, M.D., Vice President of Research & Scientific Development, will speak on "Human ESC-Derived Cells for Rescue of Visual Function and Repair of Vascular Damage,” at the 6th Annual Stem Cells & Regenerative Medicine meeting October 16-17, 2006 at the Renaissance Pittsburgh Hotel in Pittsburgh, PA. Dr. Lanza will present on Monday, October 16th at 9:30 a.m. and such presentation shall be available on the company's website. " (Click to View Presentation)":/conference-presentations/
Embryonic stem cells promise to provide a well-characterized and reproducible source of replacement tissue for human clinical studies. Two early potential applications of this technology are the use of human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) for the treatment of retinal degenerative diseases such as macular degeneration and retinitis pigmentosa, and the use of hESC-derived hemangioblasts for vascular restoration of organs and limbs. Recent progress using these cells to affect substantial functional and morphological rescue in animals will be discussed.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit "http://www.advancedcell.com":http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Investor Relations: "James Carbonara":mailto:firstname.lastname@example.org
Media Relations: "Bill Douglass":mailto:email@example.com
The Investor Relations Group
Trilogy Capital Partners